Sign In
Last checked at 
14 Apr 2026 07:45
Faron Pharmaceuticals Ltd | Company announcement | April 14, 2026 at 10:45:00 EEST
Capitalised terms used in this announcement have the meanings given to them in the announcement made on 13 April 2026 at 14:00. EEST regarding the amortisation payment and approval of share subscriptions based on special rights, unless the context provides otherwise.
Turku, Finland â€" Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company developing novel immunotherapies, has, as announced on 13 April 2026, approved the exercise of 3,572,851 Special Rights entitling to 3,572,851 new Shares, for an aggregate subscription price of EUR 1,613,499.51.
In total, 3,572,851 new Shares in the Company have today on 14 April 2026 been registered in the Finnish Trade Register. The Shares rank pari passu in all respects with the existing shares of the Company. Following the registration of new Shares, the aggregate number of ordinary shares in the Company is 161,100,740.
Furthermore, as announced by the Company on 9 April 2026 and 13 April 2026, the Company also expects to register today, 14 April 2026, a total of 41,944,771 offer shares issued as part of the rights issue. Following the registration of such offer shares, the aggregate number of ordinary shares in the Company will be 203,045,511. Shares held in treasury by the Company do not confer a right to dividends or other shareholder rights. Following the registration of the offer shares of the rights issue and new Shares as well as completion of delivery of all offer shares of the rights issue, the Company will have 3,530,573 shares in treasury and therefore, the total number of voting rights in Faron is 199,514,938 (the “Number of Shares and Votesâ€). This figure may be used by shareholders as the denominator for the calculations by which they will determine whether they are required to notify an interest in, or a change to their interest in, the Number of Shares and Votes of the Company.
Trading in the new Shares is expected to commence on First North and AIM on 15 April 2026.
For more information, please contact:
| IR Partners, Finland(Media)Kare Laukkanen | +358 50 553 9535 / +44 7 469 766 223kare.laukkanen@irpartners.fi |
| FINN Partners, US(Media) Alyssa Paldo | +1 847 791-8085 alyssa.paldo@finnpartners.com |
| Cairn Financial Advisers LLP(Nominated Adviser and Broker)Sandy Jamieson, Jo Turner | +44 (0) 207 213 0880 |
| Sisu Partners Oy(Certified Adviser on Nasdaq First North)Juha KarttunenJukka J¤rvel¤ | +358 (0)40 555 4727+358 (0)50 553 8990 |
About Faron Pharmaceuticals Ltd
Faron (AIM: FARN, First North: FARON) is a global, clinical-stage biopharmaceutical company, focused on tackling cancers via novel immunotherapies. Its mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system. The Company’s lead asset is bexmarilimab, a novel anti-Clever-1 humanized antibody, with the potential to remove immunosuppression of cancers through reprogramming myeloid cell function. Bexmarilimab is being investigated in Phase I/II clinical trials as a potential therapy for patients with hematological cancers in combination with other standard treatments. Further information is available at www.faron.com.
Follow the stocks
